Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~* 25(OH) D3 level \< 80 ng/mL~PATIENT CHARACTERISTICS:~Inclusion criteria:~* ECOG performance status 0-2~* Creatinine ≤ 2.0 mg/dL~* Corrected serum calcium ≤ 10.5 mg/dL~Exclusion criteria:~* History of malabsorption syndrome (e.g., pancreatic insufficiency, celiac disease, or tropical sprue)~* Hypersensitivity to cholecalciferol or one of its components~PRIOR CONCURRENT THERAPY:~* No other concurrent vitamin D supplementation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive 4,000 IU of oral cholecalciferol (vitamin D3) once daily.
- Arm II (Type: EXPERIMENTAL): Patients receive 6,000 IU of vitamin D3 once daily.
- Arm III (Type: EXPERIMENTAL): Patients receive 8,000 IU of vitamin D3 once daily.
- Arm IV (Type: EXPERIMENTAL): Patients receive 10,000 IU of vitamin D3 once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).